Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (9595)	11/28/2003 2:01:34 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

And here's GSK's pipeline, which also looks pretty thin to me: Reuters Cancer, heart drugs to star in Glaxo pipeline Friday November 28, 7:07 am ET LONDON, Nov 28 (Reuters) - GlaxoSmithKline Plc (London:GSK.L - News), the world's second-largest drug company, holds a research and development day in London on December 3 and in New York on December 4. The following are some of the new drugs, with code number and stage of clinical trials, which industry analysts expect to be in focus: - - - - CANCER - 572016, Phase II: a treatment for breast and other solid tumours that blocks two biological switches involved in cancer growth, EGFR and ErbB-2, which are inhibited separately in drugs such as AstraZeneca Plc's (London:AZN.L - News) Iressa and Genentech Inc's (NYSE:DNA - News) Herceptin (News - Websites) . - HPV vaccine, Phase II: a vaccine against Human Papilloma Virus for preventing cervical cancer and genital warts. There is currently no treatment for HPV, a common sexually transmitted infection that can lead to cancer in a small minority of women. - - - - CARDIOVASCULAR - 480848, Phase II: a treatment for atherosclerosis, or hardening of the arteries, that inhibits Lp-PLA2, an enzyme linked to inflammation and plaque build-up. The drug, which could be used in combination with statins, is the fruit of a collaboration with Human Genome Sciences Inc (NasdaqNM:HGSI - News). - - - - DIABETES - 677954, Phase I or II: a new kind of drug for type II diabetes, known as a dual PPAR agonist. No clinical data has so far been released but the product could lower both blood sugar levels and cholesterol. - - - - DEPRESSION - 597599, Phase II: a new type of antidepressant, known as an NK1 antagonist, that may be an improvement in terms of side effects compared with current drugs. Prospects for the class are uncertain, however, after Merck & Co Inc (NYSE:MRK - News) dropped a similar Phase III compound, aprepitant, earlier this month. - 353162, Phase I or II: a follow-on to antidepressant Wellbutrin that may mark an improvement on the original in terms of effectiveness and side effects. - - - - RESPIRATORY - 685698, Phase II: a next-generation inhaled steroid drug for asthma and other lung disorders which binds more effectively to the steroid receptor. - 842470, Phase II: a PDE4 inhibitor drug for asthma and smoker's cough. - - - - PAIN - 406381, Phase II: a second-generation COX-2 inhibitor for treating arthritis pain. GSK will need to conduct large-scale clinical studies to prove the drug's advantages. GASTROINTESTINAL - Talnetant, Phase II: a drug for irritable bowel syndrome that may also have a role in schizophrenia. Peter